One gene, one letter out of place

ZTTK Syndrome is a rare genetic condition that changes how the brain and body develop. It is present from conception, affects each person differently, and is lifelong.

The name is an initialism of the four researchers who first described it in 2016: Zhu, Tokita, Takenouchi and Kim. You will also see it written as SON-related syndrome, after the gene involved.

It was identified only as whole exome and whole genome sequencing came into wider use, which is why most clinicians have never met a patient with it. That is not a reflection of how serious it is. It is a reflection of how new the name still is.

A change in a single gene called SON, which sits on chromosome 21 at a location written 21q22.11. SON acts as a kind of editor inside the cell, helping other genes be read correctly. A great many developmental processes depend on it.

Everyone has two copies of SON. In ZTTK Syndrome one copy carries a change that stops it working. The remaining copy cannot fully cover the shortfall, and development is affected as a result.

In almost every known case the change is de novo: it appeared for the first time in that child and was not inherited from either parent. Nothing a parent did or did not do during pregnancy caused it.

Only by reading the genetic code. ZTTK Syndrome cannot be seen on a routine blood test, a scan, or the standard chromosome tests offered a generation ago. It takes exome or genome sequencing.

The usual path starts with something else: delayed milestones, low muscle tone, feeding difficulty, a seizure. Investigations follow, often for years, before sequencing is offered and a name finally appears.

That wait has a cost. A named diagnosis unlocks the right therapies, connects a family to others living the same condition, and ends the search. Shortening it is the single most useful thing wider awareness can do.

It varies widely, and that variation matters more than any list. Commonly described features include developmental delay and intellectual disability, low muscle tone, differences in brain structure seen on imaging, vision and feeding difficulties, short stature, and seizures in some children.

None of that describes a person. Children with ZTTK Syndrome learn, communicate, show preference and humour, and make progress on their own timeline. Physiotherapy, speech and language therapy, occupational therapy and good educational support all change outcomes.

What families consistently say helps most is other families. Nobody explains the day to day better than someone already living it.

September is ZTTK Syndrome Awareness Month, and the point of it is not a colour or a hashtag. It is that a condition this rare only becomes visible to clinicians when families make it visible, and visibility is what shortens the wait for the next diagnosis.

More every year. A decade ago the condition had no name. Today there are published clinical descriptions, a growing patient registry, a family foundation funding research, and new papers appearing in the literature. Around 65 patients appear in the literature, while the ZTTK SON-Shine Foundation has identified more than 250, which tells you how much of this condition is still unrecorded.

This is the ordinary arc of a rare disease, and it only moves when cases are reported and families are counted. Every diagnosis added to the record sharpens what the next family is told.

The research below is technical by design. It is here because families deserve access to the same sources their clinicians read.